STAT6 (P42226) variants and mutations
STAT6 (also known as P42226) is a human protein-coding gene encoding a signal transducer and activator of transcription 6 protein. It mediates IL-4 and IL-13 signaling that drives type 2 immunity, IgE responses, and alternative macrophage activation. Gain-of-function germline variants can cause severe early-onset allergic disease and immune dysregulation, while pathway inhibition is therapeutically useful in atopic disorders. This analysis covers 1,190 STAT6 variants and mutations. Of these, 75% have computational variant effect predictions. Disease context includes hyper-IgE syndrome 6, autosomal dominant, with recurrent infections, asthma, and diffuse large B-cell lymphoma. Example STAT6 variants include M1?, W4*, and G5C.
Variant analysis overview
- Gene: STAT6
- Protein: P42226
- UniProt accession: P42226
- Organism: Homo sapiens
- Variants analyzed: 1190
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 932 unspecified-consequence records; 1 stop lost; 1 stop retained variant; 93 synonymous variants; 15 frameshift variants; 135 missense variants; 2 in-frame insertions; 3 in-frame deletions; 5 stop-gained variants; 1 splice-region variants; 2 substitution
- Prediction scores: 890 variants have prediction scores (75% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hyper-IgE syndrome 6, autosomal dominant, with recurrent infections, asthma, diffuse large B-cell lymphoma, allergic disease, respiratory system disorder, allergic rhinitis, Wheezing, adult onset asthma, lymphoma, solitary fibrous tumor, childhood onset asthma, Hodgkins lymphoma.
Protein structure and variant hotspots
- Protein features: 1 domains; 2 post-translational modification sites.
- Structural context: 136 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable STAT6 variants
Examples include M1?, W4*, G5C, G5D, G5S, S8A, M10I, M10L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, cosmic curated COSV10809
- W4* (p.Trp4Ter), ExAC rs758360742, gnomAD rs758360742, CADD 37.00
- G5C (p.Gly5Cys), cosmic curated COSV55670
- G5D (p.Gly5Asp), cosmic curated COSV55673, REVEL 0.09, CADD 16.50
- G5S (p.Gly5Ser), ExAC rs750315001, gnomAD rs750315001, REVEL 0.15, CADD 15.90
- S8A (p.Ser8Ala), TOPMed rs2034395346
- M10I (p.Met10Ile), TOPMed rs1046376263, gnomAD rs1046376263, REVEL 0.06, CADD 18.60
- M10L (p.Met10Leu), TOPMed rs980271630, gnomAD rs980271630
- M10V (p.Met10Val), TOPMed rs980271630, gnomAD rs980271630, REVEL 0.07, CADD 20.90
- P11A (p.Pro11Ala), cosmic curated COSV55669
- P11S (p.Pro11Ser), gnomAD rs1172005597, REVEL 0.05, CADD 18.60
- P12L (p.Pro12Leu), Ensembl rs2034394238, REVEL 0.20, CADD 26.60
- E13D (p.Glu13Asp), cosmic curated COSV10027
- V15A (p.Val15Ala), gnomAD rs1242194213, REVEL 0.20, CADD 23.60
- R17Q (p.Arg17Gln), rs188884452, NCI-TCGA Cosmic COSV5567, cosmic curated COSV55671, 1000Genomes rs188884452, REVEL 0.06, CADD 19.10, Variant assessed as somatic; moderate impact.
- R17W (p.Arg17Trp), TOPMed rs1462316171, gnomAD rs1462316171, REVEL 0.24, CADD 28.70
- L18F (p.Leu18Phe), ExAC rs760282046, gnomAD rs760282046, REVEL 0.35, CADD 25.40
- Y19* (p.Tyr19Ter), TOPMed rs1565695675
- Y19C (p.Tyr19Cys), TOPMed rs1337779301, gnomAD rs1337779301, REVEL 0.69, CADD 26.00
- V20I (p.Val20Ile), ExAC rs774834215, gnomAD rs774834215, REVEL 0.08, CADD 16.80
- D21N (p.Asp21Asn), cosmic curated COSV10460, ExAC rs771572649, TOPMed rs771572649, gnomAD rs771572649, REVEL 0.09, CADD 22.70, Uncertain significance, Inborn genetic diseases
- P23L (p.Pro23Leu), gnomAD rs1454646185
- P23S (p.Pro23Ser), TOPMed rs2034391360
- Q24* (p.Gln24Ter), NCI-TCGA Cosmic COSV5566, cosmic curated COSV55669, Variant assessed as somatic; high impact.
- H25Y (p.His25Tyr), ExAC rs773786402, gnomAD rs773786402, REVEL 0.13, CADD 23.40
- R27Q (p.Arg27Gln), gnomAD rs1299643349, REVEL 0.80, AlphaMissense 0.92
- R27W (p.Arg27Trp), gnomAD rs2034390435, REVEL 0.81, CADD 31.00, Uncertain significance, Inborn genetic diseases
- H28Y (p.His28Tyr), cosmic curated COSV55671
- L29F (p.Leu29Phe), cosmic curated COSV55668
- L29V (p.Leu29Val), 1000Genomes rs544099322, ExAC rs544099322, gnomAD rs544099322, REVEL 0.18, CADD 25.10
- D32N (p.Asp32Asn), TOPMed rs2034389430
- W33C (p.Trp33Cys), ExAC rs768725046, gnomAD rs768725046, REVEL 0.65, CADD 30.00
- S36N (p.Ser36Asn), ESP rs368611496, ExAC rs368611496, TOPMed rs368611496, gnomAD rs368611496, REVEL 0.07, CADD 6.84
- P38A (p.Pro38Ala), gnomAD rs1436602071
- P38L (p.Pro38Leu), cosmic curated COSV10517
- W39C (p.Trp39Cys), gnomAD rs1353003588
- E40K (p.Glu40Lys), cosmic curated COSV55673
- E40Q (p.Glu40Gln), Ensembl rs1565695119
- F41L (p.Phe41Leu), TOPMed rs2034364842, REVEL 0.11, CADD 23.40
- G44C (p.Gly44Cys), TOPMed rs757430778, gnomAD rs757430778, REVEL 0.21, CADD 21.60, Uncertain significance
- G44S (p.Gly44Ser), rs757430778, ClinGen CA237746607, NCI-TCGA Cosmic COSV5567, cosmic curated COSV55670, REVEL 0.11, CADD 13.30, Uncertain significance, Inborn genetic diseases
- S45T (p.Ser45Thr), Ensembl rs2034363993, REVEL 0.13, CADD 22.70
- D46N (p.Asp46Asn), rs780257871, NCI-TCGA Cosmic COSV5567, cosmic curated COSV55670, ExAC rs780257871, REVEL 0.20, CADD 16.60, Variant assessed as somatic; moderate impact.
- A47S (p.Ala47Ser), NCI-TCGA Cosmic COSV5567, Variant assessed as somatic; moderate impact.
- A47T (p.Ala47Thr), cosmic curated COSV55672, ExAC rs745938816, TOPMed rs745938816, gnomAD rs745938816, REVEL 0.04, CADD 8.63
- C49G (p.Cys49Gly), cosmic curated COSV55670
- C50F (p.Cys50Phe), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10027, Variant assessed as somatic; moderate impact.
- N51S (p.Asn51Ser), Ensembl rs1592574193, REVEL 0.05, CADD 12.50
- L52V (p.Leu52Val), cosmic curated COSV55674
- A53V (p.Ala53Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S54G (p.Ser54Gly), TOPMed rs1224577652, REVEL 0.16, CADD 20.70
- S54N (p.Ser54Asn), rs575257117, NCI-TCGA Cosmic COSV5567, cosmic curated COSV55671, 1000Genomes rs575257117, REVEL 0.06, CADD 12.10, Variant assessed as somatic; moderate impact.
- S54T (p.Ser54Thr), 1000Genomes rs575257117, TOPMed rs575257117
- A55S (p.Ala55Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L56R (p.Leu56Arg), gnomAD rs1398440820, REVEL 0.38, CADD 25.30
- L57F (p.Leu57Phe), TOPMed rs1445296330
- S58L (p.Ser58Leu), rs778871413, NCI-TCGA Cosmic COSV5567, cosmic curated COSV55672, ExAC rs778871413, REVEL 0.13, CADD 27.20, Variant assessed as somatic; moderate impact.
- T60I (p.Thr60Ile), gnomAD rs1469770904, REVEL 0.16, CADD 23.50
- Q62H (p.Gln62His), 1000Genomes rs148320699, ESP rs148320699, ExAC rs148320699, TOPMed rs148320699, REVEL 0.10, CADD 22.80
- H63N (p.His63Asn), TOPMed rs1478597227, gnomAD rs1478597227, REVEL 0.09, CADD 19.20
- H63Q (p.His63Gln), ExAC rs777452521, TOPMed rs777452521, gnomAD rs777452521, REVEL 0.12, CADD 2.66, Uncertain significance, Inborn genetic diseases
- H63Y (p.His63Tyr), TOPMed rs1478597227, gnomAD rs1478597227, REVEL 0.08, CADD 22.50
- L64F (p.Leu64Phe), gnomAD rs976116452, REVEL 0.40, CADD 25.50
- L64R (p.Leu64Arg), TOPMed rs909474877, gnomAD rs909474877, REVEL 0.57, CADD 25.90
- Q65R (p.Gln65Arg), TOPMed rs985033610, REVEL 0.05, CADD 20.80
- A66P (p.Ala66Pro), ExAC rs755870689, gnomAD rs755870689, REVEL 0.05, CADD 6.64
- S67L (p.Ser67Leu), rs767265892, NCI-TCGA Cosmic COSV5567, cosmic curated COSV55670, ExAC rs767265892, REVEL 0.05, CADD 12.60, Uncertain significance, Inborn genetic diseases
- G69V (p.Gly69Val), TOPMed rs1425726773
- Q71E (p.Gln71Glu), rs2034357748, ClinGen CA385401830, ClinVar RCV004465532, Ensembl rs2034357748, AlphaMissense 0.07, MetaLR 0.13, Uncertain significance, Inborn genetic diseases
- Q71R (p.Gln71Arg), cosmic curated COSV55673
- G72R (p.Gly72Arg), Ensembl rs966116833, cosmic curated COSV10027
- G74R (p.Gly74Arg), TOPMed rs1220734568, gnomAD rs1220734568, REVEL 0.20, CADD 23.30
- T76I (p.Thr76Ile), cosmic curated COSV10027
- I81V (p.Ile81Val), ExAC rs761099650, TOPMed rs761099650, gnomAD rs761099650, REVEL 0.21, CADD 22.80, Uncertain significance, Inborn genetic diseases
- T83I (p.Thr83Ile), TOPMed rs971464970, REVEL 0.07, CADD 22.40
- L84F (p.Leu84Phe), cosmic curated COSV55673
- E85V (p.Glu85Val), Ensembl rs2034356062, REVEL 0.25, CADD 34.00
- S86I (p.Ser86Ile), gnomAD rs1232270313, REVEL 0.10, CADD 19.00
- S86N (p.Ser86Asn), NCI-TCGA Cosmic COSV5567, cosmic curated COSV55670, Variant assessed as somatic; moderate impact.
- S86R (p.Ser86Arg), TOPMed rs2034335639, REVEL 0.08, CADD 19.80
- Q89R (p.Gln89Arg), gnomAD rs1483954081, REVEL 0.09, CADD 20.30
- R90K (p.Arg90Lys), gnomAD rs1274836401, REVEL 0.13, CADD 23.70, Uncertain significance, Inborn genetic diseases
- D91E (p.Asp91Glu), rs144249360, ClinGen CA6642058, ClinVar RCV002963862, ESP rs144249360, REVEL 0.13, CADD 14.20, Uncertain significance, Inborn genetic diseases
- P92T (p.Pro92Thr), Ensembl rs2136614646
- L93R (p.Leu93Arg), rs483352723, ClinGen CA229111, ClinVar RCV000087205, Ensembl rs483352723, AlphaMissense 0.18, MetaLR 0.25, Uncertain significance, not provided
- L95M (p.Leu95Met), Ensembl rs2034333646
- V96L (p.Val96Leu), Ensembl rs1565694408, REVEL 0.17, CADD 23.10
- A97D (p.Ala97Asp), NCI-TCGA Cosmic COSV5567, cosmic curated COSV55672, Variant assessed as somatic; moderate impact.
- T98S (p.Thr98Ser), TOPMed rs937605959, gnomAD rs937605959, REVEL 0.10, CADD 17.90
- F99L (p.Phe99Leu), NCI-TCGA Cosmic COSV5567, cosmic curated COSV55671, Variant assessed as somatic; moderate impact.
- Q101* (p.Gln101Ter), cosmic curated COSV55670
- Q101R (p.Gln101Arg), ExAC rs770981602, gnomAD rs770981602, REVEL 0.17, CADD 19.80
- Q104E (p.Gln104Glu), cosmic curated COSV10027
- Q104K (p.Gln104Lys), cosmic curated COSV10589, ESP rs143832217, ExAC rs143832217, TOPMed rs143832217, REVEL 0.05, CADD 22.70
- G105V (p.Gly105Val), ExAC rs769739267, TOPMed rs769739267, gnomAD rs769739267, REVEL 0.17, CADD 25.00
- E106G (p.Glu106Gly), gnomAD rs1440890841, REVEL 0.81, CADD 29.70
- A109T (p.Ala109Thr), ExAC rs747992913, TOPMed rs747992913, gnomAD rs747992913, REVEL 0.04, CADD 23.30
- A109V (p.Ala109Val), 1000Genomes rs570858641, ExAC rs570858641, TOPMed rs570858641, gnomAD rs570858641, REVEL 0.09, CADD 19.10, Uncertain significance, Inborn genetic diseases
- M111I (p.Met111Ile), rs1165529137, ClinGen CA385401088, ClinVar RCV002714364, TOPMed rs1165529137, AlphaMissense 0.32, MetaLR 0.36, Uncertain significance, Inborn genetic diseases
- M111L (p.Met111Leu), Ensembl rs2034331384
- E112D (p.Glu112Asp), cosmic curated COSV55669
- Q113E (p.Gln113Glu), cosmic curated COSV10642, Ensembl rs2034331088, REVEL 0.05, CADD 17.60
- F114L (p.Phe114Leu), TOPMed rs1414157057, gnomAD rs1414157057, REVEL 0.26, CADD 11.80
- R115C (p.Arg115Cys), rs898004039, ClinGen CA237746414, ClinVar RCV002830979, TOPMed rs898004039, REVEL 0.22, CADD 23.30, Uncertain significance, Inborn genetic diseases
- R115H (p.Arg115His), rs766600386, ClinGen CA6642039, cosmic curated COSV55672, ClinVar RCV004465534, REVEL 0.13, CADD 4.25, Likely benign, Inborn genetic diseases
- H116Q (p.His116Gln), Ensembl rs1488057004
- H116R (p.His116Arg), TOPMed rs1040620463, gnomAD rs1040620463, REVEL 0.13, CADD 16.10
- P118L (p.Pro118Leu), ESP rs370431863, ExAC rs370431863, gnomAD rs370431863
- M119V (p.Met119Val), gnomAD rs1245688836, REVEL 0.07, CADD 12.70
- P120R (p.Pro120Arg), rs757485322, gnomAD 12-57098561-G-C, CADD 7.90
- H122Y (p.His122Tyr), cosmic curated COSV55673
- H122R (p.His122Arg), gnomAD 12-57098579-T-C, CADD 8.84
- W123* (p.Trp123Ter), cosmic curated COSV10609
- W123S (p.Trp123Ser), rs1238882001, gnomAD 12-57097106-C-G, CADD 6.29
- Q125K (p.Gln125Lys), cosmic curated COSV55669
- Q125R (p.Gln125Arg), gnomAD rs1211079828, REVEL 0.10, CADD 22.50
- E126D (p.Glu126Asp), ExAC rs769710616, TOPMed rs769710616, gnomAD rs769710616, REVEL 0.15, CADD 22.80, Uncertain significance, Inborn genetic diseases
- E126K (p.Glu126Lys), cosmic curated COSV10460
- E127* (p.Glu127Ter), NCI-TCGA Cosmic COSV5566, cosmic curated COSV55668, Variant assessed as somatic; high impact.
- L128F (p.Leu128Phe), Ensembl rs2034309094
- K129N (p.Lys129Asn), gnomAD rs1263111468, REVEL 0.12, CADD 21.50
- F130C (p.Phe130Cys), TOPMed rs1222049627, gnomAD rs1222049627, REVEL 0.32, CADD 28.90
- K131R (p.Lys131Arg), gnomAD 12-57098537-T-C, CADD 9.58
- T132I (p.Thr132Ile), gnomAD 12-57097127-G-A, CADD 8.38
- T132M (p.Thr132Met), rs12314983, gnomAD 12-57098525-G-A, CADD 1.35
- G133A (p.Gly133Ala), ExAC rs761852923, gnomAD rs761852923, REVEL 0.08, CADD 2.97
- G133D (p.Gly133Asp), cosmic curated COSV10441, ExAC rs761852923, gnomAD rs761852923, REVEL 0.10, CADD 5.59
- L134F (p.Leu134Phe), cosmic curated COSV55668, ExAC rs776641789, gnomAD rs776641789, REVEL 0.34, CADD 16.90
- R135Q (p.Arg135Gln), ExAC rs746789941, TOPMed rs746789941, gnomAD rs746789941, REVEL 0.11, CADD 5.29, Likely benign, Inborn genetic diseases
- R135W (p.Arg135Trp), rs768641653, ClinGen CA6642033, ClinVar RCV002934183, ExAC rs768641653, REVEL 0.20, CADD 23.20, Uncertain significance, Inborn genetic diseases
- R135H (p.Arg135His), rs760639049, gnomAD 12-57098558-C-T, CADD 0.90
- R135L (p.Arg135Leu), rs760639049, gnomAD 12-57098558-C-A, CADD 1.60
- R136G (p.Arg136Gly), gnomAD rs1322608384, REVEL 0.17, CADD 25.00
- R136S (p.Arg136Ser), ExAC rs779625240, REVEL 0.07, CADD 23.30
- L137V (p.Leu137Val), TOPMed rs1435974202, gnomAD rs1435974202, REVEL 0.32, CADD 24.30
- Q138P (p.Gln138Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q138* (p.Gln138Ter), rs2033598296, gnomAD 12-57098517-G-A, REVEL 0.22, CADD 23.10
- Q138R (p.Gln138Arg), rs759503637, gnomAD 12-57098540-T-C, CADD 5.37
- H139R (p.His139Arg), Ensembl rs2136612361
- R140* (p.Arg140Ter), cosmic curated COSV10589, CADD 35.00
- R140G (p.Arg140Gly), ExAC rs771728309, gnomAD rs771728309, REVEL 0.18, CADD 21.00
- R140Q (p.Arg140Gln), ExAC rs745470547, gnomAD rs745470547, REVEL 0.07, CADD 14.90
- V141A (p.Val141Ala), TOPMed rs2034305769
- V141I (p.Val141Ile), cosmic curated COSV55675, ESP rs377723871, ExAC rs377723871, TOPMed rs377723871, REVEL 0.04, CADD 12.70
- G142R (p.Gly142Arg), ExAC rs756665780, gnomAD rs756665780, REVEL 0.05, CADD 7.93
- E143D (p.Glu143Asp), rs374003960, ClinGen CA385400581, ClinVar RCV002920600, Uncertain significance, Inborn genetic diseases
- E143G (p.Glu143Gly), Ensembl rs2136612285
- H145Y (p.His145Tyr), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10027, gnomAD rs2034304576, REVEL 0.05, CADD 5.42, Variant assessed as somatic; moderate impact.
- L146F (p.Leu146Phe), gnomAD rs1387979430, REVEL 0.08, CADD 14.80
- L146I (p.Leu146Ile), gnomAD rs1387979430, REVEL 0.06, CADD 11.60
- L146R (p.Leu146Arg), cosmic curated COSV10962
- L147P (p.Leu147Pro), gnomAD 12-57097130-A-G, CADD 14.70
- R148Q (p.Arg148Gln), ExAC rs773043322, TOPMed rs773043322, gnomAD rs773043322, REVEL 0.09, CADD 14.50
- E149G (p.Glu149Gly), gnomAD rs1465000681, REVEL 0.16, CADD 24.70
- E149Q (p.Glu149Gln), Ensembl rs2626577
- A150V (p.Ala150Val), ExAC rs766612063, gnomAD rs766612063, REVEL 0.16, CADD 14.40
- A150G (p.Ala150Gly), rs143892572, gnomAD 12-57098549-G-C, CADD 10.50
- A150D (p.Ala150Asp), gnomAD 12-57098549-G-T, CADD 9.01
- L151M (p.Leu151Met), NCI-TCGA Cosmic COSV5566, cosmic curated COSV55668, Variant assessed as somatic; moderate impact.
- Q152H (p.Gln152His), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10027, Variant assessed as somatic; moderate impact.
- K153E (p.Lys153Glu), TOPMed rs2034302609, REVEL 0.07, CADD 11.80
- K153M (p.Lys153Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K153R (p.Lys153Arg), ExAC rs765359672, gnomAD rs765359672
- G154E (p.Gly154Glu), gnomAD rs915270574, REVEL 0.22, CADD 4.47
- G154R (p.Gly154Arg), Ensembl rs1592571492, REVEL 0.10, CADD 10.40
- A155T (p.Ala155Thr), gnomAD rs1340276790, REVEL 0.10, CADD 8.32
- A155V (p.Ala155Val), ExAC rs776770045, TOPMed rs776770045, gnomAD rs776770045, REVEL 0.18, CADD 13.40
- E156G (p.Glu156Gly), gnomAD rs1229227676, REVEL 0.27, CADD 22.30
- E156K (p.Glu156Lys), TOPMed rs1014541693
- A157T (p.Ala157Thr), gnomAD rs1382133707, REVEL 0.09, CADD 12.70
- G158V (p.Gly158Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V160M (p.Val160Met), Ensembl rs2034300145
- S161C (p.Ser161Cys), ExAC rs767350387, gnomAD rs767350387, REVEL 0.08, AlphaMissense 0.95
- S161N (p.Ser161Asn), rs1438998075, gnomAD 12-57097133-C-T, CADD 8.58
- S161F (p.Ser161Phe), rs200069633, gnomAD 12-57098510-G-A, CADD 8.20
- L162V (p.Leu162Val), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10027, NCI-TCGA Cosmic COSV5567, Variant assessed as somatic; moderate impact.
- H163Q (p.His163Gln), TOPMed rs2034289668
- H163Y (p.His163Tyr), ExAC rs774099315, gnomAD rs774099315, REVEL 0.05, CADD 23.20
- S164T (p.Ser164Thr), gnomAD rs1471782274, REVEL 0.04, CADD 0.56
- L165* (p.Leu165Ter), gnomAD rs1254444216, CADD 36.00
Public STAT6 analysis runs
- STAT6 analysis run — STAT6 (1,190 variants) — completed 2026-08-19